{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:32:36Z","timestamp":1782495156121,"version":"3.54.5"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T00:00:00Z","timestamp":1695772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Soft tissue sarcomas harboring <jats:italic>EWSR1::CREM<\/jats:italic> fusion are rare and challenging to treat. Pazopanib, a multi-tyrosine kinase inhibitor, is FDA-approved for advanced soft tissue sarcomas, but predictive biomarkers for its efficacy remain unidentified. We conducted a study on &amp;gt; 240,000 neoplasms submitted to Caris Life Sciences (Phoenix, AZ) to detect rearrangements using whole transcriptome sequencing. Two sarcoma-experienced, board-certified pathologists performed histological reviews, and treatment\/outcome information was collected. Among the identified cases (<jats:italic>n<\/jats:italic> = 18), we observed a diverse range of sarcoma and other cancers, including an intracranial myxoid mesenchymal tumor, mesothelioma, hyalinizing clear cell carcinomas of the head and neck, clear cell sarcomas, and undifferentiated round cell sarcomas, as well as histologically malignant tumors with epithelioid morphology. Notably, two undifferentiated, metastatic, abdominal round cell sarcoma cases treated with pazopanib demonstrated significant sustained partial response and clinical benefit. To explore the genetic factors associated with the efficacy of pazopanib in these cases, next-generation sequencing and fluorescence <jats:italic>in situ<\/jats:italic> hybridization were analyzed for alterations in the tumors. The genomic analysis provided compelling evidence confirming the presence of <jats:italic>EWSR1::CREM<\/jats:italic> fusion in both cases, with no other pathogenic gene variants or copy number alterations detected. These cases demonstrate the potential of Pazopanib as a promising therapeutic option for patients with <jats:italic>EWSR1::CREM<\/jats:italic> fusion-positive soft tissue sarcomas, including metastatic undifferentiated round cell sarcomas. The sustained clinical benefit and partial responses observed in these cases warrant further research to validate these findings and explore the wider utility of Pazopanib in this rare and challenging subset of soft tissue sarcomas. Case studies: Case 1: A 49-year-old man presented with abdominal pain, weight loss, and chronic cough. A computed tomography (CT) of the chest, abdomen, and pelvis showed multiple lung nodules and masses and a right rectus mass that was biopsied and revealed an undifferentiated round cell sarcoma with a rare fusion <jats:italic>EWSR1-CREM<\/jats:italic>. No additional pathogenic gene variants or copy number alterations were detected. He received neoadjuvant chemotherapy with three cycles of Vincristine, Adriamycin, and Ifosfamide (VAI) and seven cycles of Vincristine\/Irinotecan and Temodar (VIT). After cycle 7 of VIT, he had surgical resection of the abdominal mass and received radiation for lung metastasis. He completed 13 cycles of VIT after which he presented with progression of disease and switched to monotherapy with Pazopanib. At the time of this analysis he had stable disease for 28 months. Case 2: A 75-year-old woman presented with pelvic pain and new onset constipation. CT abdomen showed a large pelvic mass and intraperitoneal tumor spread. Exploratory laparotomy revealed a ruptured pelvic mass and a small bowel tumor. Both tumors were proved to be high-grade, poorly differentiated sarcoma. Genomic analysis demonstrated an <jats:italic>EWSR1::CREM<\/jats:italic> fusion but no other pathogenic gene variants or copy number alterations. She was treated initially for a primitive neuroectodermal tumor (PNET) with four cycles of Vincristine\/Adriamycin\/Cytoxan\/Olaratumab but declined additional chemotherapy after progression. Two years later, she presented with recurrent abdominal mass and received one cycle of Temodar\/Irinotecan, then she began Pozapanib and underwent palliative radiation to the entire pelvis. She has been on Pazopanib for 23 months with stable disease.<\/jats:p>","DOI":"10.3389\/fonc.2023.1215003","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:59:16Z","timestamp":1695880756000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Leticia","family":"Campoverde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Alessandrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Elliot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2020","journal-title":"Pathologica"},{"key":"B2","article-title":"Molecular classification of soft tissue sarcomas and its clinical applications","volume":"3","author":"Jain","year":"2010","journal-title":"Int J Clin Exp Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22239","article-title":"EWSR1 fusions: Ewing sarcoma and beyond","volume":"128","author":"Jo","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000788","article-title":"EWSR1 fusions with CREB family transcription factors define a novel myxoid mesenchymal tumor with predilection for intracranial location","volume":"41","author":"Kao","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0646-5","article-title":"EWSR1\/FUS-CREB fusions define a distinctive Malignant epithelioid neoplasm with predilection for mesothelial-lined cavities","volume":"33","author":"Argani","year":"2020","journal-title":"Mod Pathol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13000-018-0752-6","article-title":"Detection of specific gene rearrangements by fluorescence in situ hybridization in 16 cases of clear cell sarcoma of soft tissue and 6 cases of clear cell sarcoma-like gastrointestinal tumor","volume":"13","author":"Segawa","year":"2018","journal-title":"Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001114","article-title":"Molecular profiling of hyalinizing clear cell carcinomas revealed a subset of tumors harboring a novel EWSR1-CREM fusion: report of 3 cases","volume":"42","author":"Chapman","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001331","article-title":"Expanding the phenotypic spectrum of mesenchymal tumors harboring the EWSR1-CREM fusion","volume":"43","author":"Yoshida","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","article-title":"Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action","volume":"13","author":"Gotink","year":"2010","journal-title":"Angiogenesis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial","volume":"21","author":"Weiss","year":"2020","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000001322","article-title":"Assessment of predictive biomarkers of the response to pazopanib based on an integrative analysis of high-grade soft-tissue sarcomas: analysis of a tumor sample from a responder and patients with other soft-tissue sarcomas","volume":"478","author":"Suehara","year":"2020","journal-title":"Clin Orthop Relat Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.03.013","article-title":"Activity of sunitinib in extraskeletal myxoid chondrosarcoma","volume":"50","author":"Stacchiotti","year":"2014","journal-title":"Eur J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000449204","article-title":"Activity of c-met\/ALK inhibitor crizotinib and multi-kinase VEGF inhibitor pazopanib in metastatic gastrointestinal neuroectodermal tumor harboring EWSR1-CREB1 fusion","volume":"91","author":"Subbiah","year":"2016","journal-title":"Oncology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-3329-4-7","article-title":"Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience","volume":"4","author":"Frezza","year":"2014","journal-title":"Clin Sarcoma Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12504","article-title":"Intracranial myxoid mesenchymal tumors with EWSR1-CREB family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity","volume":"28","author":"Bale","year":"2018","journal-title":"Brain Pathol"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.96.4.1433","article-title":"Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes","volume":"96","author":"Beier","year":"1999","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1215003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T05:59:19Z","timestamp":1695880759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1215003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,27]]},"references-count":17,"alternative-id":["10.3389\/fonc.2023.1215003"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1215003","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,27]]},"article-number":"1215003"}}